sentence1
stringlengths 35
423
| sentence2
stringlengths 34
427
| score
int64 -1
1
|
|---|---|---|
Physical activity is associated with lower odds of early and late AMD in white populations. | There is no evidence that physical activity is associated with lower odds of early and late AMD in white populations. | 0 |
Physical activity is associated with lower odds of early and late AMD in white populations. | Physical activity may be associated with lower odds of early and late AMD in white populations. | 1 |
Compared with ranibizumab, corticosteroid implant did not have greater improved BCVA, but corticosteroid implant had less CST reduction. | Compared with ranibizumab, corticosteroid implant had greater improved BCVA, but corticosteroid implant had less CST reduction. | -1 |
Compared with ranibizumab, corticosteroid implant did not have greater improved BCVA, but corticosteroid implant had less CST reduction. | Compared with ranibizumab, corticosteroid implant did not have reduced BCVA, but corticosteroid implant had less CST reduction. | -1 |
Compared with ranibizumab, corticosteroid implant did not have greater improved BCVA, but corticosteroid implant had less CST reduction. | There is no evidence that compared with ranibizumab, corticosteroid implant did not have greater improved BCVA, but corticosteroid implant had less CST reduction. | 0 |
Latanoprost is more effective than brimonidine as monotherapy in lowering IOP. | Latanoprost is not more effective than brimonidine as monotherapy in lowering IOP. | -1 |
Latanoprost is more effective than brimonidine as monotherapy in lowering IOP. | Latanoprost is less effective than brimonidine as monotherapy in lowering IOP. | -1 |
Latanoprost is more effective than brimonidine as monotherapy in lowering IOP. | There is no evidence that latanoprost is more effective than brimonidine as monotherapy in lowering IOP. | 0 |
Latanoprost is more effective than brimonidine as monotherapy in lowering IOP. | Latanoprost may be more effective than brimonidine as monotherapy in lowering IOP. | 1 |
IVB/IVT is more effective for improving VA and decreasing CMT at 3 months in DME. | IVB/IVT is not more effective for improving VA and decreasing CMT at 3 months in DME. | -1 |
IVB/IVT is more effective for improving VA and decreasing CMT at 3 months in DME. | IVB/IVT is less effective for improving VA and decreasing CMT at 3 months in DME. | -1 |
IVB/IVT is more effective for improving VA and decreasing CMT at 3 months in DME. | There is no evidence that IVB/IVT is more effective for improving VA and decreasing CMT at 3 months in DME. | 0 |
IVB/IVT is more effective for improving VA and decreasing CMT at 3 months in DME. | IVB/IVT may be more effective for improving VA and decreasing CMT at 3 months in DME. | 1 |
A single injection of TA along with the first IVB could improve outcome within 3 months, but this is not sustained at 6 months. | A single injection of TA along with the first IVB improved outcome within 3 months, but this is not sustained at 6 months. | 1 |
A single injection of TA along with the first IVB could improve outcome within 3 months, but this is not sustained at 6 months. | A single injection of TA along with the first IVB could improve outcome within 3 months, but this might not be sustained at 6 months. | 1 |
Anti-VEGF drugs are effective at improving vision in people with DMO with three to four in every 10 people likely to experience an improvement of 3 or more lines VA at one year. | Anti-VEGF drugs are not effective at improving vision in people with DMO with three to four in every 10 people likely to experience an improvement of 3 or more lines VA at one year. | -1 |
Anti-VEGF drugs are effective at improving vision in people with DMO with three to four in every 10 people likely to experience an improvement of 3 or more lines VA at one year. | Anti-VEGF drugs may be effective at improving vision in people with DMO with three to four in every 10 people likely to experience an improvement of 3 or more lines VA at one year. | 1 |
Results of subgroup analysis by ethnicity revealed positive correlations between the SERPING1 rs2511989 polymorphism and risk of AMD among Caucasians under five genetic models (all p<0.05), but not among Asians (all p>0.05). | Results of subgroup analysis by ethnicity revealed negative correlations between the SERPING1 rs2511989 polymorphism and risk of AMD among Caucasians under five genetic models (all p<0.05), but not among Asians (all p>0.05). | -1 |
Meta-analyses showed that flavonoids have a promising role in improving visual function in patients with glaucoma and ocular hypertension (OHT), and appear to play a part in both improving and slowing the progression of visual field loss. | Meta-analyses showed that flavonoids do not have a promising role in improving visual function in patients with glaucoma and ocular hypertension (OHT), and appear to play a part in both improving and slowing the progression of visual field loss. | -1 |
Meta-analyses showed that flavonoids have a promising role in improving visual function in patients with glaucoma and ocular hypertension (OHT), and appear to play a part in both improving and slowing the progression of visual field loss. | Meta-analyses showed that flavonoids have a promising role in decreasing visual function in patients with glaucoma and ocular hypertension (OHT), and appear to play a part in both improving and slowing the progression of visual field loss. | -1 |
Meta-analyses showed that flavonoids have a promising role in improving visual function in patients with glaucoma and ocular hypertension (OHT), and appear to play a part in both improving and slowing the progression of visual field loss. | Meta-analyses showed that flavonoids have an important role in improving visual function in patients with glaucoma and ocular hypertension (OHT), and appear to play a part in both improving and slowing the progression of visual field loss. | 1 |
Meta-analyses showed that flavonoids have a promising role in improving visual function in patients with glaucoma and ocular hypertension (OHT), and appear to play a part in both improving and slowing the progression of visual field loss. | Meta-analyses showed that flavonoids have a promising role in improving visual function in patients with glaucoma and ocular hypertension (OHT), but do not appear to play a part in both improving and slowing the progression of visual field loss. | -1 |
Meta-analyses showed that flavonoids have a promising role in improving visual function in patients with glaucoma and ocular hypertension (OHT), and appear to play a part in both improving and slowing the progression of visual field loss. | Meta-analyses showed that flavonoids have a promising role in improving visual function in patients with glaucoma and ocular hypertension (OHT), and play a part in both improving and slowing the progression of visual field loss. | 1 |
Combination therapy decreased the number of injections of ranibizumab, although its BCVA improvement was inferior to that of monotherapy over 12 months of follow-up. Given the inherent limitations of the included trials, more studies are needed to further validate and update the findings in this area. | Combination therapy did not decrease the number of injections of ranibizumab, although its BCVA improvement was inferior to that of monotherapy over 12 months of follow-up. Given the inherent limitations of the included trials, more studies are needed to further validate and update the findings in this area. | -1 |
Combination therapy decreased the number of injections of ranibizumab, although its BCVA improvement was inferior to that of monotherapy over 12 months of follow-up. Given the inherent limitations of the included trials, more studies are needed to further validate and update the findings in this area. | Combination therapy increased the number of injections of ranibizumab, although its BCVA improvement was inferior to that of monotherapy over 12 months of follow-up. Given the inherent limitations of the included trials, more studies are needed to further validate and update the findings in this area. | -1 |
Combination therapy decreased the number of injections of ranibizumab, although its BCVA improvement was inferior to that of monotherapy over 12 months of follow-up. Given the inherent limitations of the included trials, more studies are needed to further validate and update the findings in this area. | Combination therapy decreased the number of injections of ranibizumab, and its BCVA improvement was not inferior to that of monotherapy over 12 months of follow-up. Given the inherent limitations of the included trials, more studies are needed to further validate and update the findings in this area. | -1 |
Combination therapy decreased the number of injections of ranibizumab, although its BCVA improvement was inferior to that of monotherapy over 12 months of follow-up. Given the inherent limitations of the included trials, more studies are needed to further validate and update the findings in this area. | Combination therapy decreased the number of injections of ranibizumab, and its BCVA improvement was superior to that of monotherapy over 12 months of follow-up. Given the inherent limitations of the included trials, more studies are needed to further validate and update the findings in this area. | -1 |
A substantial number of patients with occult CNV from AMD will develop at least moderate visual loss at 1 year and severe visual loss within 3 years. | A substantial number of patients with occult CNV from AMD will not develop at least moderate visual loss at 1 year and severe visual loss within 3 years. | -1 |
A substantial number of patients with occult CNV from AMD will develop at least moderate visual loss at 1 year and severe visual loss within 3 years. | A small number of patients with occult CNV from AMD will develop at least moderate visual loss at 1 year and severe visual loss within 3 years. | -1 |
A substantial number of patients with occult CNV from AMD will develop at least moderate visual loss at 1 year and severe visual loss within 3 years. | There is no evidence that a substantial number of patients with occult CNV from AMD will develop at least moderate visual loss at 1 year and severe visual loss within 3 years. | 0 |
A substantial number of patients with occult CNV from AMD will develop at least moderate visual loss at 1 year and severe visual loss within 3 years. | A substantial number of patients with occult CNV from AMD may develop at least moderate visual loss at 1 year and severe visual loss within 3 years. | 1 |
This meta-analysis disclosed a stronger effect of ARMS2 genotypes in RAP cases compared with CFH Y402H and I62V genotypes. | This meta-analysis did not disclose a stronger effect of ARMS2 genotypes in RAP cases compared with CFH Y402H and I62V genotypes. | -1 |
This meta-analysis disclosed a stronger effect of ARMS2 genotypes in RAP cases compared with CFH Y402H and I62V genotypes. | This meta-analysis disclosed a weaker effect of ARMS2 genotypes in RAP cases compared with CFH Y402H and I62V genotypes. | -1 |
This meta-analysis disclosed a stronger effect of ARMS2 genotypes in RAP cases compared with CFH Y402H and I62V genotypes. | There is no evidence of a stronger effect of ARMS2 genotypes in RAP cases compared with CFH Y402H and I62V genotypes. | 0 |
As primary therapy of OAG or OHT, SLT is no more effective than PGA in success rate. | As primary therapy of OAG or OHT, SLT is more effective than PGA in success rate. | -1 |
As primary therapy of OAG or OHT, SLT is no more effective than PGA in success rate. | As primary therapy of OAG or OHT, SLT is no less effective than PGA in success rate. | -1 |
As primary therapy of OAG or OHT, SLT is no more effective than PGA in success rate. | There is no evidence that as primary therapy of OAG or OHT, SLT is no more effective than PGA in success rate. | 0 |
As primary therapy of OAG or OHT, SLT is no more effective than PGA in success rate. | As primary therapy of OAG or OHT, SLT may be no more effective than PGA in success rate. | 1 |
IOP reduction affected by SLT is not effective than PGA. | IOP reduction affected by SLT is more effective than PGA. | -1 |
IOP reduction affected by SLT is not effective than PGA. | IOP reduction affected by SLT is not more ineffective than PGA. | -1 |
IOP reduction affected by SLT is not effective than PGA. | There is no evidence that IOP reduction affected by SLT is more effective than PGA. | 0 |
IOP reduction affected by SLT is not effective than PGA. | IOP reduction affected by SLT may not be more effective than PGA. | 1 |
Compared with PGA, SLT can reduce the use of anti-glaucoma medications. | Compared with PGA, SLT can not reduce the use of anti-glaucoma medications. | -1 |
Compared with PGA, SLT can reduce the use of anti-glaucoma medications. | Compared with PGA, SLT can increase the use of anti-glaucoma medications. | -1 |
Compared with PGA, SLT can reduce the use of anti-glaucoma medications. | There is no evidence that compared with PGA, SLT can reduce the use of anti-glaucoma medications. | 0 |
Compared with PGA, SLT can reduce the use of anti-glaucoma medications. | Compared with PGA, SLT may reduce the use of anti-glaucoma medications. | 1 |
This meta-analysis suggested that CX3CR1 T280M and V249I polymorphisms may not be associated with an increased risk of AMD based on current published data. | This meta-analysis suggested that CX3CR1 T280M and V249I polymorphisms may be associated with an increased risk of AMD based on current published data. | -1 |
This meta-analysis suggested that CX3CR1 T280M and V249I polymorphisms may not be associated with an increased risk of AMD based on current published data. | This meta-analysis suggested that CX3CR1 T280M and V249I polymorphisms may not be associated with a decreased risk of AMD based on current published data. | -1 |
This meta-analysis suggested that CX3CR1 T280M and V249I polymorphisms may not be associated with an increased risk of AMD based on current published data. | This meta-analysis suggested that CX3CR1 T280M and V249I polymorphisms is not be associated with an increased risk of AMD based on current published data. | 1 |
This review provides some limited evidence that control of IOP is better with trabeculectomy than viscocanalostomy. | This review provides some limited evidence that control of IOP is not better with trabeculectomy than viscocanalostomy. | -1 |
This review provides some limited evidence that control of IOP is better with trabeculectomy than viscocanalostomy. | This review provides some limited evidence that control of IOP is worse with trabeculectomy than viscocanalostomy. | -1 |
This review provides some limited evidence that control of IOP is better with trabeculectomy than viscocanalostomy. | There is no evidence that control of IOP is better with trabeculectomy than viscocanalostomy. | 0 |
This review provides some limited evidence that control of IOP is better with trabeculectomy than viscocanalostomy. | This review provides strong evidence that control of IOP is better with trabeculectomy than viscocanalostomy. | 1 |
Phaco-GSL might be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP seems superior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | Phaco-GSL might not be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP seems superior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | -1 |
Phaco-GSL might be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP seems superior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | Phaco-GSL is an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP seems superior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | 1 |
Phaco-GSL might be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP seems superior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | Phaco-GSL might be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP seems not superior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | -1 |
Phaco-GSL might be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP seems superior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | Phaco-GSL might be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP seems inferior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | -1 |
Phaco-GSL might be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP seems superior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | Phaco-GSL might be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP is superior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | 1 |
Phaco-GSL might be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP seems superior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | Phaco-GSL might be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP seems superior to Phaco alone and inferior to Phaco-trabeculectomy/trabeculectomy. | -1 |
Phaco-GSL might be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP seems superior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | Phaco-GSL might be an optimal procedure to treat ACG with concomitant cataract due to its bleb-less nature, and its capacity for lowering IOP is superior to Phaco alone and comparable to Phaco-trabeculectomy/trabeculectomy. | 1 |
Anticipated discomfort is often greater than actual discomfort experienced during intra-vitreal injection. | Anticipated discomfort is not often greater than actual discomfort experienced during intra-vitreal injection. | -1 |
Anticipated discomfort is often greater than actual discomfort experienced during intra-vitreal injection. | Anticipated discomfort is often less than actual discomfort experienced during intra-vitreal injection. | -1 |
Anticipated discomfort is often greater than actual discomfort experienced during intra-vitreal injection. | There is no evidence that anticipated discomfort is greater than actual discomfort experienced during intra-vitreal injection. | 0 |
Anticipated discomfort is often greater than actual discomfort experienced during intra-vitreal injection. | Anticipated discomfort may be often greater than actual discomfort experienced during intra-vitreal injection. | 1 |
However, different stages of the treatment procedure produce varying levels of patient discomfort. | However, different stages of the treatment procedure may produce varying levels of patient discomfort. | 1 |
Latanoprost is effective at reducing the IOP of patients with angle-closure glaucoma. | Latanoprost is not effective at reducing the IOP of patients with angle-closure glaucoma. | -1 |
Latanoprost is effective at reducing the IOP of patients with angle-closure glaucoma. | Latanoprost is effective at increasing the IOP of patients with angle-closure glaucoma. | -1 |
Latanoprost is effective at reducing the IOP of patients with angle-closure glaucoma. | There is no evidence that latanoprost is effective at reducing the IOP of patients with angle-closure glaucoma. | 0 |
Latanoprost is effective at reducing the IOP of patients with angle-closure glaucoma. | Latanoprost may be effective at reducing the IOP of patients with angle-closure glaucoma. | 1 |
Pooled evidence confirmed that conbercept was superior to ranibizumab with respect to visual gain after treatment. | Pooled evidence confirmed that conbercept was not superior to ranibizumab with respect to visual gain after treatment. Additional studies with long-term follow-up are needed to support our conclusion. | -1 |
Pooled evidence confirmed that conbercept was superior to ranibizumab with respect to visual gain after treatment. | Pooled evidence confirmed that conbercept was inferior to ranibizumab with respect to visual gain after treatment. Additional studies with long-term follow-up are needed to support our conclusion. | -1 |
PEXG is associated with elevated plasma tHcy and low serum folic acid levels, but not serum vitamin B12, vitamin B6 levels, and MTHFR C677T genotype. | PEXG is associated with decreased plasma tHcy and low serum folic acid levels, but not serum vitamin B12, vitamin B6 levels, and MTHFR C677T genotype. | -1 |
PEXG is associated with elevated plasma tHcy and low serum folic acid levels, but not serum vitamin B12, vitamin B6 levels, and MTHFR C677T genotype. | PEXG may be associated with elevated plasma tHcy and low serum folic acid levels, but not serum vitamin B12, vitamin B6 levels, and MTHFR C677T genotype. | 1 |
This meta-analysis strongly suggests improved VA outcomes at 12 months in patients with wet AMD for 2.0 mg aflibercept, comparable to but slightly lower than landmark trials. | This meta-analysis strongly suggests decreased VA outcomes at 12 months in patients with wet AMD for 2.0 mg aflibercept, comparable to but slightly lower than landmark trials. | -1 |
This meta-analysis strongly suggests improved VA outcomes at 12 months in patients with wet AMD for 2.0 mg aflibercept, comparable to but slightly lower than landmark trials. | This meta-analysis suggests improved VA outcomes at 12 months in patients with wet AMD for 2.0 mg aflibercept, comparable to but slightly lower than landmark trials. | 1 |
The summary mean difference indicated a statistically significant reduction in CSMT at 6 weeks when treated with bevacizumab compared to control. | The summary mean difference did not indicate a statistically significant reduction in CSMT at 6 weeks when treated with bevacizumab compared to control. | -1 |
The summary mean difference indicated a statistically significant reduction in CSMT at 6 weeks when treated with bevacizumab compared to control. | The summary mean difference indicated a statistically significant increase in CSMT at 6 weeks when treated with bevacizumab compared to control. | -1 |
The summary mean difference indicated a statistically significant reduction in CSMT at 6 weeks when treated with bevacizumab compared to control. | There is no evidence of a statistically significant reduction in CSMT at 6 weeks when treated with bevacizumab compared to control. | 0 |
Combination therapy of IVB and IVT did not result in any significant reduction in CSMT or gain in vision compared to treatment with IVB alone at any point in time. | Combination therapy of IVB and IVT resulted in a significant reduction in CSMT and gain in vision compared to treatment with IVB alone at any point in time. | -1 |
Combination therapy of IVB and IVT did not result in any significant reduction in CSMT or gain in vision compared to treatment with IVB alone at any point in time. | Combination therapy of IVB and IVT did not result in any significant increase in CSMT or decrease in vision compared to treatment with IVB alone at any point in time. | -1 |
Combination therapy of IVB and IVT did not result in any significant reduction in CSMT or gain in vision compared to treatment with IVB alone at any point in time. | There is no evidence that combination therapy of IVB and IVT did not result in any significant reduction in CSMT or gain in vision compared to treatment with IVB alone at any point in time. | 0 |
Combination therapy of IVB and IVT did not result in any significant reduction in CSMT or gain in vision compared to treatment with IVB alone at any point in time. | Combination therapy of IVB and IVT may not result in any significant reduction in CSMT or gain in vision compared to treatment with IVB alone at any point in time. | 1 |
There is no significant difference in IOP reduction between 1- and 2-site phacotrabeculectomy. | There is a significant difference in IOP reduction between 1- and 2-site phacotrabeculectomy. | -1 |
There is no significant difference in IOP reduction between 1- and 2-site phacotrabeculectomy. | There is no evidence of significant difference in IOP reduction between 1- and 2-site phacotrabeculectomy. | 0 |
There is no significant difference in IOP reduction between 1- and 2-site phacotrabeculectomy. | There may be no significant difference in IOP reduction between 1- and 2-site phacotrabeculectomy. | 1 |
Ranibizumab was non-significantly superior to aflibercept and both anti-VEGF therapies had statistically superior efficacy to laser. | Ranibizumab was non-significantly superior to aflibercept and both anti-VEGF therapies did not have statistically superior efficacy to laser. | -1 |
Ranibizumab was non-significantly superior to aflibercept and both anti-VEGF therapies had statistically superior efficacy to laser. | Ranibizumab was non-significantly superior to aflibercept and both anti-VEGF therapies had statistically inferior efficacy to laser. | -1 |
In this meta-analysis of anti-VEGF agents for patients with DME, assessment of the highest-level exposure group (those high-risk patients with DME who received 2 years of monthly treatment) revealed a possible increased risk for death and potentially for cerebrovascular accidents. | In this meta-analysis of anti-VEGF agents for patients with DME, assessment of the highest-level exposure group (those high-risk patients with DME who received 2 years of monthly treatment) did not reveal a possible increased risk for death and potentially for cerebrovascular accidents. | -1 |
In this meta-analysis of anti-VEGF agents for patients with DME, assessment of the highest-level exposure group (those high-risk patients with DME who received 2 years of monthly treatment) revealed a possible increased risk for death and potentially for cerebrovascular accidents. | In this meta-analysis of anti-VEGF agents for patients with DME, assessment of the highest-level exposure group (those high-risk patients with DME who received 2 years of monthly treatment) revealed a possible decreased risk for death and potentially for cerebrovascular accidents. | -1 |
In this meta-analysis of anti-VEGF agents for patients with DME, assessment of the highest-level exposure group (those high-risk patients with DME who received 2 years of monthly treatment) revealed a possible increased risk for death and potentially for cerebrovascular accidents. | In this meta-analysis of anti-VEGF agents for patients with DME, assessment of the highest-level exposure group (those high-risk patients with DME who received 2 years of monthly treatment) revealed an increased risk for death and potentially for cerebrovascular accidents. | 1 |
Our meta-analysis provides strong evidence that the TNF-α -308G/A polymorphism is not associated with different forms of glaucoma risk. | Our meta-analysis provides strong evidence that the TNF-α -308G/A polymorphism is associated with different forms of glaucoma risk. | -1 |
Our meta-analysis provides strong evidence that the TNF-α -308G/A polymorphism is not associated with different forms of glaucoma risk. | There is no evidence that the TNF-α -308G/A polymorphism is not associated with different forms of glaucoma risk. | 0 |
Our meta-analysis provides strong evidence that the TNF-α -308G/A polymorphism is not associated with different forms of glaucoma risk. | Our meta-analysis provides some evidence that the TNF-α -308G/A polymorphism may not be associated with different forms of glaucoma risk. | 1 |
Intraoperative MMC reduces the risk of surgical failure in eyes that have undergone no previous surgery and in eyes at high risk of failure. | Intraoperative MMC does not reduce the risk of surgical failure in eyes that have undergone no previous surgery and in eyes at high risk of failure. | -1 |
Intraoperative MMC reduces the risk of surgical failure in eyes that have undergone no previous surgery and in eyes at high risk of failure. | Intraoperative MMC increases the risk of surgical failure in eyes that have undergone no previous surgery and in eyes at high risk of failure. | -1 |
Intraoperative MMC reduces the risk of surgical failure in eyes that have undergone no previous surgery and in eyes at high risk of failure. | There is no evidence that MMC reduces the risk of surgical failure in eyes that have undergone no previous surgery and in eyes at high risk of failure. | 0 |
Intraoperative MMC reduces the risk of surgical failure in eyes that have undergone no previous surgery and in eyes at high risk of failure. | Intraoperative MMC may reduce the risk of surgical failure in eyes that have undergone no previous surgery and in eyes at high risk of failure. | 1 |
Compared to placebo it reduces mean IOP at 12 months in all groups of participants in this review. | Compared to placebo it does not reduce mean IOP at 12 months in all groups of participants in this review. | -1 |
Compared to placebo it reduces mean IOP at 12 months in all groups of participants in this review. | Compared to placebo it increases mean IOP at 12 months in all groups of participants in this review. | -1 |
Compared to placebo it reduces mean IOP at 12 months in all groups of participants in this review. | There is no evidence that compared to placebo it reduces mean IOP at 12 months in all groups of participants in this review. | 0 |